← All trials
NCT05582031
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2025
- First posted
- Oct 17, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 322
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Translational Research in OncologyLead sponsor
- BayerCollaborator
- Vall d'Hebron Institute of Research, Galatea ClinicStudy chair
- Vall d'Hebron Institute of Research, Galatea ClinicOfficial
- NovartisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.